ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Advaxis, Inc.

305 College Road East
Princeton, NJ 08540
United States
609-452-9813
http://www.advaxis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees58

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth A. Berlin J.D.Pres, CEO & Director447.46kN/A1964
Ms. Molly Henderson CPA, CPA, MBAExec. VP, CFO & Corp. Sec.186.87kN/A1971
Dr. Robert G. PetitChairman of Scientific Advisory Board480.69kN/A1960
Dr. Andres A. GutierrezExec. VP & Chief Medical OfficerN/AN/A1961
Ms. Ranya DajaniVP of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc., as well as a research collaboration agreement with the University of California Los Angeles. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Corporate Governance

Advaxis, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.